Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Renal Cell
  • Interferon-alpha
  • Isotretinoin
  • Kidney Neoplasms

abstract

  • Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC. 13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors. Treatment, particularly the combination therapy, was associated with a decrease in QOL.

publication date

  • September 4, 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10944130

Additional Document Info

start page

  • 2972

end page

  • 80

volume

  • 18

number

  • 16